Emer­gent scores a DoD award to eval­u­ate its chikun­gun­ya vac­cine in the field

Emer­gent BioSo­lu­tions is look­ing to make progress with its chikun­gun­ya vac­cine and has re­ceived a $10 mil­lion US gov­ern­ment grant to help it along.

Emer­gent an­nounced that it has been hand­ed a re­search award from the De­part­ment of De­fense’s Con­gres­sion­al Di­rect­ed Med­ical Re­search Pro­grams to eval­u­ate the ef­fi­ca­cy of its sin­gle-dose chikun­gun­ya virus vac­cine can­di­date.

The plan­ning phase will be done in col­lab­o­ra­tion with the Armed Forces Re­search In­sti­tute of Med­ical Sci­ences (AFIRMS) and oth­er aca­d­e­m­ic part­ners to kick off a “post-ap­proval field ef­fi­ca­cy study.” The study is to be done in ar­eas with ac­tive chikun­gun­ya virus trans­mis­sion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER